Chemonucleolysis for relief of sciatica due to a herniated intervertebral disc

Area of Science:

• Neurosurgery
• Pain Management
• Enzymatic Therapy

Background:

• Sciatica caused by herniated lumbar discs is a common condition.
• Nonoperative treatments are sought to manage leg pain and neurological deficits.
• Chemonucleolysis offers a minimally invasive chemical approach to disc removal.

Purpose of the Study:

• To evaluate the efficacy and safety of chemonucleolysis for sciatica.
• To determine the success rate and complication profile of chymopapain treatment.
• To assess the long-term outcomes and failure rates of chemonucleolysis.

Main Methods:

• A randomized study of 220 patients with confirmed sciatica due to herniated discs.
• Exclusion criteria included psychogenic pain, spinal stenosis, and prior surgery.
• Chymopapain was administered for nonoperative chemical removal of displaced disc material.

Main Results:

• Chemonucleolysis demonstrated an 80% success rate in eligible patients.
• The primary complications were anaphylactic reactions in two patients and delayed reactions in five.
• The long-term treatment failure rate was low at 1.4% after subsequent surgeries for unsuccessful cases.

Conclusions:

• Chemonucleolysis is an effective nonoperative treatment for sciatica caused by herniated lumbar discs.
• Chymopapain has a favorable safety profile with manageable complications.
• This procedure provides a successful alternative to surgery for many patients with sciatica.